Oral Inhalation System Delivers Morphine Doses

Oncology NEWS InternationalOncology NEWS International Vol 9 No 2
Volume 9
Issue 2

VIENNA, Austria-A new oral inhalation system for morphine is almost as efficient as IV dosing, Aradigm Corp and SmithKline Beecham researchers reported at the 9th World Congress on Pain. B. A. Otulana, MD, said that the dose-corrected bioavailability of morphine with the new device was 75% of that with intravenous morphine, a major increase over the 5% bioavailability achieved with other nebulizers. This approach might provide a useful, noninvasive alternative to parenteral morphine administration.

VIENNA, Austria—A new oral inhalation system for morphine is almost as efficient as IV dosing, Aradigm Corp and SmithKline Beecham researchers reported at the 9th World Congress on Pain. B. A. Otulana, MD, said that the dose-corrected bioavailability of morphine with the new device was 75% of that with intravenous morphine, a major increase over the 5% bioavailability achieved with other nebulizers. This approach might provide a useful, noninvasive alternative to parenteral morphine administration.

The Aradigm device uses disposable liquid dosage forms and a hand-held nebulizer to produce fine aerosol particles that can penetrate deep into the lungs. It was tested in comparison to intravenous morphine in 10 healthy adult subjects in an open-label crossover trial.

On separate days, subjects took either 4 mg of morphine IV or four inhalations of aerosolized morphine (a total dose of 8.8 mg). Plasma morphine levels were measured at baseline and for 4 hours after dosing. Both inhaled and intravenous morphine reached peak plasma concentrations in less than 2 minutes after dosing. Dr. Otulana said that relative Cmax (ng/mL) bioavailability of the inhaled dose was 78%, while the area under the curve (AUC) ratio was 163.8% (Table).

This suggests that, at least in healthy volunteers, the morphine inhalation device provides efficient delivery of morphine and a pharmacokinetic profile similar to that of intravenous morphine, Dr. Otulana concluded.

Related Videos
Experts on multiple myeloma
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Experts on multiple myeloma
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
Experts on MM
Experts on colorectal cancer
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma